Article

KRAS status in patients with colorectal cancer peritoneal carcinomatosis and its impact on outcome.

Department of Surgery, Walter Reed Army Medical Center, United States Military Cancer Institute, Washington, DC, USA.
American journal of clinical oncology (impact factor: 2.21). 11/2009; 33(5):456-60. DOI:10.1097/COC.0b013e3181b4b160 pp.456-60
Source: PubMed

ABSTRACT KRAS mutated colorectal cancers (CRC) are reported to be associated with a poor response to anti-EGFR monoclonal antibody therapy and poor prognosis. We studied the rates of KRAS mutated tumors in patients with peritoneal carcinomatosis from CRC and investigated the association of KRAS status with specific clinicopathologic factors.
A retrospective observational study of tumor specimens from 23 patients with peritoneal carcinomatosis from CRC was performed using standard genomic DNA sampling techniques to identify KRAS mutations. Correlation between clinicopathologic factors and KRAS mutation status was performed using the Fisher exact test or χ test, as appropriate.
Eleven (48%) of 23 patients had KRAS mutations. There were no statistically significant correlations in patient demographics, tumor pathology, surgical evaluation, treatments, or survival outcomes for peritoneal carcinomatosis between patients with KRAS mutations or wild-type KRAS status.
The prevalence of KRAS mutation in CRC patients with peritoneal carcinomatosis is 48% in this preliminary study and clinicopathologic factors appear to be independent of mutation status.

0 0
 · 
0 Bookmarks
 · 
34 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

anti-EGFR monoclonal antibody therapy
 
clinicopathologic factors
 
CRC patients
 
Fisher exact test
 
KRAS mutated colorectal cancers
 
KRAS mutated tumors
 
KRAS mutation
 
KRAS mutation status
 
KRAS mutations
 
KRAS status
 
poor response
 
retrospective observational study
 
specific clinicopathologic factors
 
standard genomic DNA sampling techniques
 
statistically significant correlations
 
surgical evaluation
 
survival outcomes
 
tumor pathology
 
tumor specimens
 
wild-type KRAS status